- 133.9k views
HRD Evaluation in 4 types of Cancers
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.
About the Speaker
Dr. Shibichakravarthy Kannan
Precision Oncology, Founder & CEO in Oncophenomics Inc., Hyderabad
Upcoming Case Discussions
Gynaecologist’s Guide to Ovarian Cancer
Join us for a special webinar on World Ovarian Cancer Day, titled "Gynaecologist’s Guide to Ovarian Cancer." This expert-led session will delve into the latest advancements in early diagnosis, risk stratification, and evidence-based management of ovarian cancer. Tailored for gynecologists and healthcare professionals, the session will also explore real-world case discussions and multidisciplinary treatment approaches. Let’s come together to raise awareness and empower clinicians in the fight against this silent but deadly disease
Massive Transfusion Protocol
Massive Transfusion Protocol (MTP) is a standardized medical procedure activated in cases of severe hemorrhage, typically involving the rapid administration of large volumes of blood products. The goal is to restore circulating volume, maintain hemostasis, and prevent the lethal triad of hypothermia, acidosis, and coagulopathy. MTP usually involves a balanced ratio of packed red blood cells, plasma, and platelets, often in a 1:1:1 ratio. Early activation and coordination among trauma teams, laboratory services, and blood banks are essential for its success.
Sleep Apnea and Daytime Fatigue
Sleep Disorder Breathing is a term for a group of conditions with abnormal breathing patterns during sleep. This affects everyday functioning and well being.There are few types of SDB which include upper airways resistance, hypopnea, apnea, catathrenia and heavy snoring. People suffering with SDB can have daytime symptoms that result in poor sleep also. There can also be sleepiness, depressed mood, irritability and cognitive dysfunction.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Shibichakravarthy Kannan 's Talks on Assimilate
- 18th-July-2023, TIME : 5:00PM - 6:00PM
- 0
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.
- 18th-July-2023, TIME : 5:00PM - 6:00PM
- 0
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.
- 18th-July-2023, TIME : 5:00PM - 6:00PM
- 0
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.
- 18th-July-2023, TIME : 5:00PM - 6:00PM
- 0
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.